Renal protective effect of Samsca in patients with new-onset acute heart failure

Renal protective effect of tolvaptan in patients with new-onset acute heart failure - Renal protective effect of tolvaptan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036417

Enrollment

150

Registered

2019-05-15

Start date

2019-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized with new-onset acute heart failure NYHA 3 or 4 Less than 40mg dose of furosemide prescribed at admission

Exclusion criteria

Exclusion criteria: Concomitant acute coronary syndrome History of tolvaptan treatment before hospitalization Hemodialysis patient

Design outcomes

Primary

Measure	Time frame
Incidence of worsening renal function during hospitalization between tolvaptan group and furosemide group	—

Secondary

Measure	Time frame
Composite outcome (all cause mortality, heart failure rehospitalization and renal impairment) All cause mortality Heart failure rehospitalization Renal impairment	—

Countries

Japan

Contacts

Public ContactShinobu Bandou

Kansai Medical University Medical Center Department of Cardiology

bandoshi@takii.kmu.ac.jp+81-6-6992-1001

Outcome results